Coffee Creamer Recalled as FDA Sets Highest Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A nondairy coffee creamer sold across the Northeast has been recalled after it was found that it could pose serious health risks to consumers with milk allergies.
MO-CHA brand Premium Non-Dairy Creamer, imported by Momo Tea Inc. of Maspeth, New York, was voluntarily recalled after it was found to contain undeclared milk ingredients.
On Tuesday, the Food and Drug Administration (FDA) classified the recall as Class I, its most serious designation.
Newsweek has contacted Momo Tea Inc via social media for comment.
Why It Matters
Federal food labeling regulations require that all major allergens, including milk, be clearly disclosed on packaging. The recalled product includes milk-derived ingredients, whey powder and casein, but does not declare milk as an allergen on its label.
This type of labeling omission can be life-threatening for individuals with milk allergies as food allergy symptoms can include hives, rashes, vomiting, diarrhea, stomach cramps, respiratory issues and, in severe cases, anaphylaxis—a condition marked by throat swelling, a drop in blood pressure, difficulty breathing and loss of consciousness.
File photo: milk being poured into a mug of coffee.
File photo: milk being poured into a mug of coffee.
Agencia el Universal/GDA via AP
What To Know
The affected product, which was imported from China and packaged in 2.2-pound bags, has a shelf life of two years.
There are no lot codes or unique identifiers listed in the recall notice. According to the FDA, all units of the product on the market are subject to the recall, with about 4,500 cases distributed across New York, New Jersey and Connecticut.
Momo Tea Inc. initiated the recall on April 10, and the FDA released its classification on April 22.
FDA's classification indicates a reasonable probability that consumption could cause severe health consequences or death, as a Class I recall determines "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death."
Ingredients listed on the product label include glucose syrup, refined vegetable oil, whey powder, sugar and various food additives.
What People Are Saying
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last 5, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
According to the FDA's notice, the recall is still ongoing.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
1.7 Million Cartons of Eggs Recalled for Salmonella Contamination
On June 6, the United States Food & Drug Administration (FDA) announced that August Egg Company of Hilmar, CA, is recalling 1.7 million dozen cage-free and certified organic eggs. The brown eggs, which were distributed in at least nine states, have been linked to a salmonella outbreak. According to the Centers for Disease Control & Prevention (CDC), there have been 79 reported salmonella infections so far, with 21 of those people being Name: Various brands of cage-free and organic eggs Date of Recall: June 6, 2025 Plant Code Number: P-6562 or CA5330 Distribution: Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington, WyomingSalmonella can cause severe gastrointestinal symptoms, such as stomach cramps, diarrhea, and fever. The symptoms of salmonella can start anywhere from six hours after eating contaminated food to six days after exposure. The recalled eggs were distributed in California and Nevada from February 3, 2025 to May 15, 2025 with sell by dates of March 4, 2025 to June 4, 2025, The eggs were sold at grocers including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less, and Ralphs. The eggs were also distributed in Walmart stores from February 3, 2025 to May 6, 2025 with sell-by dates from March 4, 2025 to June 19, 2025. Walmarts in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois sold the recalled eggs. This recall affects numerous brands of eggs, including Simply Truth Organic, which is sold at Kroger stores, and Marketside, which is sold at Walmart. Check for a full list of brands affected by the recall. If you have one of the affected cartons of eggs in your fridge, do not eat them. Instead, the FDA recommends returning the eggs to your place of purchase for a refund. If you have questions about this recall, contact August Egg Company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Read the original article on SIMPLYRECIPES
Health Line
2 hours ago
- Health Line
Is There an Azstarys Shortage?
Azstarys is a prescription drug used to treat ADHD. Some ADHD medications have recently been in short supply. Learn whether Azstarys is affected and how to check its availability. Azstarys is not currently listed in the Food and Drug Administration (FDA) drug shortages database. Here's what to know about why some ADHD medications may be hard to find and how to check for drug shortages. Is there a shortage of other ADHD drugs? In recent years, several ADHD medications have been in short supply. A few examples include Adderall, Concerta, Ritalin, and Vyvanse. It's not yet clear when these shortages will fully resolve. These shortages have affected both brand-name and generic versions of the drugs. As a result, some people have worked with their doctor to switch to a different medication or adjust their ADHD treatment plan. To check the current status of Aztarys and other ADHD medications, visit the FDA drug shortages website. How do ADHD drug shortages affect people? Shortages of ADHD medications can make it harder for people to stick with their treatment plan. This can cause ADHD symptoms to return or become more difficult to manage. A lack of consistent access to ADHD medication may also increase stress and affect mental health. Other possible effects of disrupted access to ADHD medication include: difficulty focusing or completing daily tasks increased impulsivity or emotional outbursts difficulty falling or staying asleep withdrawing from social, family, or work activities If you're having trouble filling a prescription for an ADHD medication, talk with your doctor or pharmacist. They may recommend alternatives or adjust your treatment plan based on what's available. What causes a drug shortage? Several factors can lead to a medication being in short supply. Common causes of ADHD drug shortages include: Increased demand: More people receiving diagnoses of ADHD have led to greater demand for medications. This can strain manufacturers and reduce availability at pharmacies. Regulatory limits: Stimulant medications used to treat ADHD, including Azstarys, are controlled substances. The Drug Enforcement Administration (DEA) sets yearly production limits for these medications. If demand rises suddenly, these limits may contribute to shortages. Supply chain issues: Shortages of raw materials, packaging supplies, or labor can delay the manufacturing and availability of ADHD drugs. When multiple ADHD medications are in short supply at the same time, it can be especially hard for pharmacies to keep any option in stock. Even when generic forms are available, they may be affected by the same issues as brand-name drugs. As a result, generics may be just as difficult to find during a shortage. How can I check whether Azstarys is available near me? Azstarys is not currently listed by the FDA as being in shortage. However, some people may still experience delays when trying to fill their prescription. Availability can vary depending on your pharmacy, location, and insurance plan. If you're having trouble finding Azstarys, start by talking with a pharmacist. If possible, visit the pharmacy in person. Some pharmacies may not share inventory details for ADHD medications over the phone. You can also check pharmacy websites or apps, which sometimes offer tools to look up availability online. Keep in mind that availability may change as new shipments arrive. You can also check with your insurance provider. If Azstarys isn't available through your plan's preferred pharmacy, your insurer may be able to help you locate another pharmacy. In some cases, you may want to reach out to the drug manufacturer for information about availability in your area. To learn more about contacting the manufacturer, visit the Azstarys website.
Miami Herald
2 hours ago
- Miami Herald
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer SAN FRANCISCO, CA / ACCESS Newswire / June 9, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap on the company's assessment of the in-person Type C Meeting on May 28, 2025 with the Division of Gastroenterology of the U.S. Food and Drug Administration (FDA) to discuss the statistically significant responder analysis results for adult patients with breast cancer in Napo's recently conducted Phase 3 OnTarget trial. "We were very happy to take part in the face-to-face Type C Meeting, the catalyst for which was the positive data in the subpopulation of breast cancer patients from our OnTarget trial," said Lisa Conte, Jaguar's founder, president, and CEO. "Napo proposed two simultaneous potential pathways during the meeting for making crofelemer available to metastatic breast cancer patients with the significant unmet medical need of CTD: conducting a pivotal treatment trial to facilitate approval of crofelemer for CTD in this focused patient population; and the prompt pursuit of authorization to initiate an expanded access program for breast cancer patients with CTD who may not be eligible for this study, including breast cancer patients in the adjuvant and neoadjuvant settings. We are pleased with the constructive and productive discussion that took place with the FDA during the meeting. Last week the FDA formally acknowledged both of these key discussion points in correspondence to Napo. We plan to submit a protocol to the FDA for a pivotal treatment trial for a smaller number of metastatic breast cancer patients using crofelemer." Patient advocates participated in the Type C Meeting to share their raw and personal experience with CTD, including a metastatic breast cancer patient with uncontrollable diarrhea who received a prescription for crofelemer. "The design of the protocol for OnTarget was based on a survey of cancer patients. Today there are close to 100 approved targeted cancer agents. Thanks to these amazing drugs, metastatic cancer patients are living longer, frequently rendering cancer, and CTD, chronic ailments with which to live. To deepen our understanding of the current population of metastatic cancer breast with CTD, and ensure the clinical meaningfulness of the design of the anticipated pivotal treatment trial, we plan to conduct a new survey of this cancer patient population," Conte said. The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with the company's core focus on orphan diseases. The company therefore intends to request orphan drug designation from the FDA for the CTD indication in this population. Given crofelemer's novel and paradigm-shifting mechanism of action, the company also plans to seek Breakthrough Therapy designation and/or Fast Track designation from the FDA to support potentially expedited regulatory approval in the US for crofelemer for CTD in metastatic breast cancer patients. "Embracing a sharp strategic focus on orphan indications seems to fit with the new administration's efforts and philosophy," said Conte. "Dr. Marty Makary, the new Commissioner of the FDA, commented in April 2025 that the agency will open a new regulatory pathway based on what he called a 'plausible mechanism,' focusing mainly on rare or incurable diseases." As expressed during the Type C Meeting, the data from the first-of-its-kind prophylactic OnTarget study is invaluable, providing new insights into the natural history of the important and debilitating side effect of CTD. Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, and often cessation of lifesaving cancer therapy. The benefit to risk ratio of crofelemer is well-documented, as the active agent has been commercialized for the approved indication of HIV-related diarrhea since 2012, with no crofelemer-related reported serious adverse events. In both the US and European Union, crofelemer has been granted orphan drug designation for the orphan diseases of short bowel syndrome with intestinal failure and microvillus inclusion disease. Crofelemer has been granted orphan drug designation for treatment of diarrhea in cholera in the US, where cholera is an orphan disease. Orphan drug designation in the US qualifies the sponsor of a drug for various development incentives, including tax credits for qualified clinical testing and relief of filing fees. Additionally, orphan drug designation in the US provides a seven-year period of marketing exclusivity to the first sponsor who obtains marketing approval for the designated orphan drug. While the multicenter, double-blind, placebo-controlled OnTarget pivotal trial did not meet its primary endpoint, the subgroup of adult breast cancer patients achieved statistically significant results in the responder analysis. In the responder analysis of patients with breast cancer on targeted therapies, crofelemer CTD prophylaxis resulted in a greater proportion of monthly responders of diarrhea improvement compared to placebo. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial of crofelemer for diarrhea in adults with 10 solid tumor types receiving targeted therapy with or without standard chemotherapy. The OnTarget results in breast cancer patients were the subject of a poster presentation on December 11, 2024, at the San Antonio Breast Cancer Symposium, and additional significant results in adult breast cancer patients from the OnTarget study have been accepted for presentation as an oral rapid e-poster at the Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting in June 2025 in Seattle, Washington. About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the currently estimated US metastatic breast cancer population qualifies as an orphan population, Jaguar's expectation that the company will submit a protocol to the FDA for a pivotal treatment trial for a smaller number of metastatic breast cancer patients using crofelemer, Jaguar's expectation that it will promptly pursue authorization to initiate an expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer patients, and that the expanded access program would potentially include breast cancer patients in the adjuvant and neoadjuvant settings, Jaguar's expectation that Napo will conduct a clinical trial of crofelemer for treatment of CTD in patients with metastatic breast cancer, Jaguar's plans to seek Breakthrough Therapy designation and/or Fast Track designation from the FDA to support potentially expedited regulatory approval in the US for crofelemer for CTD in metastatic breast cancer patients, and Jaguar's expectation that additional significant results in adult breast cancer patients from the OnTarget study will be presented at the 2025 MASCC Annual Meeting. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
